Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease

NCT02339415 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Inflammation
Coagulation
HIV Infection

Interventions

DRUG: Edoxaban 30mg daily
DRUG: Matching placebo

Sponsor

Hennepin Healthcare Research Institute